rivaroxaban and Cholangiocarcinoma

rivaroxaban has been researched along with Cholangiocarcinoma* in 2 studies

Other Studies

2 other study(ies) available for rivaroxaban and Cholangiocarcinoma

ArticleYear
Intrahepatic Cholangiocarcinoma Associated Paradoxical Peripheral Embolism and a Submassive Pulmonary Embolism.
    Annals of vascular surgery, 2019, Volume: 61

    Paradoxical peripheral embolism and submassive pulmonary embolism (PE), secondary to cancer-associated thrombosis, are yet to be reported in the literature. Here we describe a case presenting with an acute peripheral arterial embolism. Subsequent testing revealed a PE and an intrahepatic cholangiocarcinoma as the likely risk factors for thrombus, with arterial spread likely achieved through a patent foramen ovale. The patient's symptoms almost relieved upon catheter-directed thrombus fragmentation and aspiration, catheter-directed thrombolysis, and combined anticoagulation. Embolism and major bleeding did not occur during 6 months of follow-up under systemic anticoagulation with rivaroxaban. This case documents that catheter-directed thrombolysis and anticoagulation could be likely effective and safe in the treatment and prevention of recurrence of paradoxical embolism and PE secondary to cancer-associated thrombosis.

    Topics: Bile Duct Neoplasms; Cholangiocarcinoma; Embolism, Paradoxical; Factor Xa Inhibitors; Female; Humans; Middle Aged; Pulmonary Embolism; Rivaroxaban; Thrombolytic Therapy; Thrombosis; Treatment Outcome

2019
Prothrombin complex concentrate and fatal thrombotic adverse events: A complication to keep in mind.
    Drug discoveries & therapeutics, 2018, May-13, Volume: 12, Issue:2

    Thromboembolic events such as deep vein thrombosis and pulmonary embolism are well-known complications that can occur after prothrombin complex concentrate therapy. However, acute myocardial infarction is a very rare but potentially life-threatening complication that was exclusively described in patients with bleeding disorders who received chronic and recurrent concentrate infusions. We report the case of a 70 year-old male patient with cholangiocarcinoma who was admitted to our hospital with worsening fatigue and weakness. His stay was complicated by uncontrolled bleeding secondary to rivaroxaban use and advanced liver disease. By the end of the prothrombin complex concentrate infusion used to reverse his coagulopathy, patient developed ST-segment elevation myocardial infarction with cardiogenic shock and passed away. This is the first reported case of acute myocardial infarction that occurs in a patient without hemophilia and after the first prothrombin complex concentrate infusion.

    Topics: Aged; Bile Duct Neoplasms; Blood Coagulation Factors; Cholangiocarcinoma; Fatal Outcome; Hemorrhage; Humans; Male; Rivaroxaban; Shock, Cardiogenic; ST Elevation Myocardial Infarction

2018